Phenominer Database Results (22 results)

 
 
Table "column sort" updates the order of the bars in the chart.
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 70.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68198 829
DA.ACI-(D10Rat2-D10Rat6) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68207 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 30.8 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days relap, % 68228 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 81.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68225 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68732 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 3 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68721 839
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 56.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68210 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 40.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68216 829
DA.ACI-(D10Rat10-D10Rat142) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 71.4 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68219 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68204 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 11 91.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 CMO:0001402 68135 839
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 87.5 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68709 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 0.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68733 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 25.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days expressed as a fraction of total number of animals 68231 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 1 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68729 839
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 6 50.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 CMO:0001402 68713 839
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 12 8.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68195 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68201 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 30.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68213 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 87.5 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68717 839
DA.ACI-(D10Rat12-D10Rat144) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 38.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days relap, % 68222 829
DA/Ztm percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 56.0 % in vivo visual assessment 0.0 0 69951 1258